# Dose-Ranging Study Evaluating AVE1625 in Abdominally Obese Patients With Atherogenic Dyslipidemia

> **NCT00345410** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 345 (actual)

## Conditions studied

- Obesity
- Dyslipidemia

## Interventions

- **DRUG:** AVE1625 B

## Key facts

- **NCT ID:** NCT00345410
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2007-06
- **Final completion:** 2007-06
- **Target enrollment:** 345 (ACTUAL)
- **Last updated:** 2008-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00345410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00345410, "Dose-Ranging Study Evaluating AVE1625 in Abdominally Obese Patients With Atherogenic Dyslipidemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00345410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*